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Background: The metabolic syndrome is a cluster of risk factors that is responsible for most of the excess cardiovascular morbidity 
amongst persons with type 2 Diabetes Mellitus (DM). The metabolic syndrome increases the risk for coronary heart disease and stroke by 
three-fold with a marked increase in cardiovascular mortality. 
Objectives: This study set out to find the prevalence of the metabolic syndrome amongst type 2 diabetes mellitus patients and the 
commonest metabolic abnormalities in them in Uyo, South-South Nigeria. 
Subjects and Methods: A prospective cross sectional study carried out at the diabetes clinic of the University of Uyo Teaching Hospital, 
between January and August, 2008. Data obtained included anthropometric indices, blood pressure and fasting serum lipids. Data was 
analyzed using SPSS version 10. 
Results: Two hundred and forty subjects (106 males, 134 females) were enrolled for the study. The prevalence of metabolic syndrome was 
62.5%. . Majority of the subjects with metabolic syndrome were aged between 41-70 years with a mean age of. 53±7years. Hypertension 
was the most common metabolic abnormality present in 130 (86.6%) of the subjects with metabolic syndrome, while low high density 
lipoprotein (HDL) was the least common abnormality present in 26 (17.3%) of the subjects with metabolic syndrome. Two metabolic 
abnormalities were present in 114 (76%) of the subjects, while four abnormalities were present in 4 (2.6%) of the subjects with metabolic 
syndrome. 
Conclusion: The prevalence of metabolic syndrome in type 2 DM patients in Uyo, South-South of Nigeria is high. With the cardiovascular 
risk associated with this syndrome, efforts must be geared towards addressing these abnormalities through lifestyle modification, health 
awareness and medications in order to reduce this complication in type 2 DM patients. 
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INTRODUCTION
Type 2 Diabetes Mellitus is a heterogeneous metabolic 
disorder characterized by chronic hyperglycemia due to dynamic 
interactions between varying degrees of insulin secretion and 
insulin resistance. Either of these defects may be the predominant 
feature in a particular case (1-4). The metabolic syndrome, also 
called insulin resistance syndrome or syndrome X, is a cluster of 
risk factors that is responsible for much of the excess 
cardiovascular disease morbidity amongst overweight and obese 
patients and those with type 2 Diabetes Mellitus (5). 
The metabolic syndrome is defined when three or more of the 
following are present (6):
· Abdominal obesity with waist circumference for men >102cm 
and women >88cm. 
· Serum Triglyceride >1.7mmol/l. 
· High density, lipoprotein (HDL) cholesterol for men 
<0.9mmol/l and for women <1.0mmol/l.
· Blood pressure >130/85mmHg. 
· Fasting plasma glucose > 110mg/dl. 
The importance of the metabolic syndrome lies in the fact that 
each individual component carries a grave risk for vascular events 
and the combination has a synergistic effect (7). 
This study therefore set out to find the prevalence of metabolic 
syndrome amongst persons with type 2 DM, and the commonest 
metabolic abnormality in these persons and to compare this with 
findings elsewhere where such studies have been done. 
SUBJECTS AND METHODS
This was a cross sectional, prospective study carried out at 
the Diabetes clinic of the University of Uyo Teaching Hospital. 
The study was carried out between January and August, 2008. 
Informed consent was obtained from the subjects after the study 
guidelines had been explained to them. Patients who were not 
more than 70 years of age, and have had type 2 DM for not less 
than 6 months were enrolled for the study. A brief clinical history 
was obtained from the subjects while anthropometric indices and 
blood pressure was measured. Weight in kilogrammes and height 
in metres was obtained from the weighing scale and stadiometer, 
respectively. The waist circumference was taken as the midpoint 
between the rib cage and iliac crest while hip circumference was 
taken as the maximal circumference around the buttocks 
posteriorly and pubic symphysis anteriorly (8). Blood pressure 
was measured in the sitting position with a mercury 
sphygmomanometer and hypertension diagnosed if patient has 
been on antihypertensive drugs, or had a blood pressure reading 
of >130mmHg systolic and/or diastolic blood pressure of 
>85mmHg. Serum lipids were taken after at least an 8 hour fast. 
Metabolic syndrome was diagnosed using the ATP criteria (5,6). 
Since all the patients were diabetic, the presence of two 
metabolic abnormalities other than diabetes was enough to 
establish the diagnosis of metabolic syndrome.  Data analysis 
was done using SPSS version 10 and results were presented in a 
tabulated form. The level of statistical significance was taken as 
pd”0.05. 
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RESULTS
A total of two hundred and forty subjects were enrolled for the 
study. These were one hundred and six (106) males and one 
hundred and thirty four (134) females giving a male: female ratio of 
1:1.2. The mean age of the study subjects was 50.8±11 years. One 
hundred and fifty (150) persons had metabolic syndrome giving a 
prevalence of 62.5%. The mean age of the subjects with metabolic 
syndrome was 53±7 years (table 1), the mean body mass index was 
228.7±6.4kg/m  while the mean waist hip ratio was 0.94±0.08. This 
is shown in table 1.   There were forty-four males and one hundred 
and six females with metabolic syndrome giving a male: female 
ratio of 1:2.4. Majority of the subjects (77.3%) were aged between 
41 – 70 years.  The age distribution is shown in table 2. Fifty four 
(36%) of subjects with metabolic syndrome had generalized 
obesity, while 102 (72%) were centrally obese using waist 
circumference, and 1.6 (84%) using waist hip ratio. The age 
distribution of the subjects with metabolic syndrome is shown in 
table 2. 
Hypertension was the commonest metabolic abnormality 
present in 86.6% of the subjects, while low HDL cholesterol was 
the least common abnormality present in 17.3% of the subjects. 
The distribution of the metabolic abnormalities is shown in table 3. 
Two metabolic abnormalities were present in 114 (76%) subjects; 
three abnormalities in 22 (14.6%) subjects while only 4 (2.6%) 
subjects had four metabolic abnormalities. 
Table 1: Clinical Characteristics of subjects with metabolic 
syndrome (n=150)
Parameter Mean±SD
Age (years) 53 ± 7
2BMI (kg/m ) 28.7±6.4
WHR 0.94±0.08
BMI: Body Mass Index
WHR: Waist hip ratio
Table 2: Age and distribution of patients with metabolic 
syndrome
Age No (%) 
<30 2 (1.33)
31 – 40 32 (21.3)
41 – 50 38 (25.3)
51 – 60 40 (26.6)
61 – 70 38 (25.3) 
Metabolic Men Women Total
Abnormality
Hypertension 44 86 130
High Triglyceride 32 40 72
Abdominal Obesity 12 100 112
Low HDL 12 14 26
Table 3: Prevalence of different components of the metabolic 
Syndrome amongst Type 2 DM patients 
* Hypertension:  > 130/85mmHg  
* High Triglyceride: > 1.7mmol/l   
* Abdominal Obesity  Male: >102cm,  
        Female: >88cm
* Low HDL                 Male: < 0.9mmol/l
         Female: <0.1mmol/l
HDL: High density lipoprotein
DISCUSSION
The metabolic syndrome is a complex combination of 
entities including abdominal obesity, atherogenic dyslipidaemia, 
elevated blood pressure, insulin resistance plus glucose 
intolerance and a prothrombotic and proinflammatory state that 
affects all ages (6). This syndrome is also known as “syndrome 
X”, “insulin resistance syndrome”, the “deadly quartet”, 
“cardiometabolic  syndrome”, “Reaven’s syndrome” amongst 
others (6). Various organizations have published criteria for 
diagnosis of the metabolic syndrome including the World Health 
Organization (WHO), the National Cholesterol Education 
Programme (NCEP) and the American Association of Clinical 
Endocrinologists (AACE) (6,9,10). Initially called syndrome X in 
1988 by Reaven, each component of the syndrome has been 
associated with an increased risk of cardiovascular disease 
.(11,12).
The prevalence of metabolic syndrome in this study is 62.5%. 
In similar studies amongst type 2 DM subjects in Iraq, a high 
prevalence rate of 86%, was seen, while a lower prevalence rate of 
56% was seen in patients of Saudi Arabian origin (13,14). A 
similar study done amongst type 2 diabetes patients in Lagos, 
Nigeria reported a prevalence rate of 51% (15). The prevalence of 
the metabolic syndrome is strongly dependent on the definition 
that is used to diagnose the syndrome. The high prevalence in our 
study could be due to rapid urbanization and adoption of 
unhealthy lifestyle amongst our people like physical inactivity, 
sedentary behaviour and unhealthy dietary habits, which 
predispose individuals to obesity. More females than males had 
metabolic syndrome giving a male to female ratio of 1:2.4. The 
higher ratio of females may be due to the fact that Nigerian women 
seek medical attention more than their male counterparts. This is 
similarly reported from the study in Lagos, Nigeria (15). Majority 
of our subjects with metabolic syndrome were aged between 41-
70 years with a mean age of 53±7 years. Metabolic syndrome 
prevalence increases with age. Our findings, are similar to that of 
Adediran et al., in which majority of those with metabolic 
syndrome were over 60 years with a mean age of 59 ±12 years, 
while in the Saudi Arabian study, the mean age was 60 ±13 years 
confirming the fact that metabolic syndrome is more common 
amongst the elderly (14,15). 86.6% of the subjects had 
hypertension and this was the commonest metabolic abnormality. 
Hypertension is an important cardiovascular risk factor on its 
own, and in combination with insulin resistance in these patients 
will have a synergistic effect and carry a grave risk for severe 
vascular events. Adediran et al., reported that 59% of the subject 
had hypertension, while Mansour reported a rate of 76% amongst 
subjects with metabolic syndrome in his study (13,15). Low HDL 
was the least common metabolic abnormality seen in our study, 
and this was similar to the findings by Mansour in Iraq (13). The 
clinical importance of the metabolic syndrome is related to its 
putative impact on cardiovascular morbidity and mortality. In a 
Scandinavian study it was shown that the prevalence of coronary 
heart disease, myocardial infarction and stroke was 
approximately threefold higher in subjects with the metabolic 
syndrome than in those without the syndrome (14). Management 
of the metabolic syndrome includes dietary modification, 
exercise and medications which reduce insulin resistance and this 
will reduce the morbidity and mortality associated with this 
syndrome. 
CONCLUSION
The metabolic syndrome is common amongst type 2 DM 
patients in Uyo. Efforts should be intensified in educating patients 
about lifestyle modifications and treatment offered to these 
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patients to reduce the excess cardiovascular risk that is associated 
with this condition. 
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